Brief post-stressor treatment with pregabalin in an animal model for PTSD: short-term anxiolytic effects without long-term anxiogenic effect. 2008

Joseph Zohar, and Michael A Matar, and Gal Ifergane, and Zeev Kaplan, and Hagit Cohen
The Chaim Sheba Medical Center, Sackler Medical School, Tel-Aviv University, Israel.

BACKGROUND The short- and long-term behavioral effects of a brief course of pregabalin, an antiepileptic structural analogue of alpha-aminobyturic acid with analgesic and anxiolytic effects, were assessed in an animal model of post-traumatic stress disorder (PTSD). METHODS Two-hundred thirty-three adult male Sprague-Dawley rats were employed. Behavioral responses to traumatic stress exposure (predator urine scent) were assessed immediately after (1 h) and 30 days after treatment with saline or pregabalin (at doses of 30, 100 and 300 mg/kg) in terms of behavior in the elevated plus maze (EPM) and the acoustic startle response (ASR) paradigms. At day 31 the freezing response to a trauma cue (clean cat litter) was assessed. The same treatment regimen initiated at day 7 was assessed at day 30 and in response to the trauma cue on day 31 in a separate experiment. RESULTS In the short term, doses of 100 mg/kg and 300 mg/kg of pregabalin effectively attenuated anxiety-like behaviors. In the longer-term, pregabalin did not attenuate the onset of PTSD-like behaviors or the prevalence rates of severe cue-responses, for either the immediate or the delayed treatment regimens. CONCLUSIONS Pregabalin may present an alternative compound for acute anxiolytic treatment after exposure to trauma, but has no long-term protective/preventive effects.

UI MeSH Term Description Entries
D008297 Male Males
D012022 Reflex, Acoustic Intra-aural contraction of tensor tympani and stapedius in response to sound. Acoustic Reflex
D003463 Cues Signals for an action; that specific portion of a perceptual field or pattern of stimuli to which a subject has learned to respond. Cue
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D005680 gamma-Aminobutyric Acid The most common inhibitory neurotransmitter in the central nervous system. 4-Aminobutyric Acid,GABA,4-Aminobutanoic Acid,Aminalon,Aminalone,Gammalon,Lithium GABA,gamma-Aminobutyric Acid, Calcium Salt (2:1),gamma-Aminobutyric Acid, Hydrochloride,gamma-Aminobutyric Acid, Monolithium Salt,gamma-Aminobutyric Acid, Monosodium Salt,gamma-Aminobutyric Acid, Zinc Salt (2:1),4 Aminobutanoic Acid,4 Aminobutyric Acid,Acid, Hydrochloride gamma-Aminobutyric,GABA, Lithium,Hydrochloride gamma-Aminobutyric Acid,gamma Aminobutyric Acid,gamma Aminobutyric Acid, Hydrochloride,gamma Aminobutyric Acid, Monolithium Salt,gamma Aminobutyric Acid, Monosodium Salt
D000069583 Pregabalin A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA. (R-)-3-isobutyl GABA,(S)-3-(aminomethyl)-5-methylhexanoic acid,(S+)-3-isobutyl GABA,3-(aminomethyl)-5-methylhexanoic acid,3-isobutyl GABA,CI 1008,CI-1008,Lyrica,1008, CI,3 isobutyl GABA,CI1008,GABA, 3-isobutyl
D000161 Acoustic Stimulation Use of sound to elicit a response in the nervous system. Auditory Stimulation,Stimulation, Acoustic,Stimulation, Auditory
D000704 Analysis of Variance A statistical technique that isolates and assesses the contributions of categorical independent variables to variation in the mean of a continuous dependent variable. ANOVA,Analysis, Variance,Variance Analysis,Analyses, Variance,Variance Analyses
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Joseph Zohar, and Michael A Matar, and Gal Ifergane, and Zeev Kaplan, and Hagit Cohen
March 1994, Pharmacology, biochemistry, and behavior,
Joseph Zohar, and Michael A Matar, and Gal Ifergane, and Zeev Kaplan, and Hagit Cohen
July 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,
Joseph Zohar, and Michael A Matar, and Gal Ifergane, and Zeev Kaplan, and Hagit Cohen
September 2019, Psychiatry research,
Joseph Zohar, and Michael A Matar, and Gal Ifergane, and Zeev Kaplan, and Hagit Cohen
November 2018, Psychiatry research,
Joseph Zohar, and Michael A Matar, and Gal Ifergane, and Zeev Kaplan, and Hagit Cohen
January 2015, European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
Joseph Zohar, and Michael A Matar, and Gal Ifergane, and Zeev Kaplan, and Hagit Cohen
January 1993, Journal of studies on alcohol,
Joseph Zohar, and Michael A Matar, and Gal Ifergane, and Zeev Kaplan, and Hagit Cohen
October 2018, Depression and anxiety,
Joseph Zohar, and Michael A Matar, and Gal Ifergane, and Zeev Kaplan, and Hagit Cohen
August 2018, Metabolic brain disease,
Joseph Zohar, and Michael A Matar, and Gal Ifergane, and Zeev Kaplan, and Hagit Cohen
December 2011, Neuropharmacology,
Joseph Zohar, and Michael A Matar, and Gal Ifergane, and Zeev Kaplan, and Hagit Cohen
August 1993, Hepato-gastroenterology,
Copied contents to your clipboard!